市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (GB) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | SYNAIRGEN PLC ORD 1P | - | - |
AIStockmoo 评分
0.8
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.0 |
| 平均 | 0.75 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| SYNAIRGEN PLC ORD 1P | 12 M | - | - | 1.21 |
| ARROWHEAD PHARMACEUTICALS INC A | 2 B | - | - | - |
| RELIEF THERAPEUTICS HOLDING SA | 2 B | - | - | - |
| IDORSIA LTD IDORSIA N ORD SHS | 1 B | - | - | - |
| OXFORD NANOPORE TECHNOLOGIES PL | 1 B | - | - | 2.97 |
| BASILEA PHARMACEUTICA AG BASILE | 560 M | - | - | - |
|
Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 0.57% |
| 机构持股比例 | 87.22% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合